|Articles|June 1, 2002
ISTA acquires rights to 3 ophthalmic compounds
Irvine, CA-ISTA Pharmaceuticals, Irvine, CA, entered into an agreement with AcSentient Inc. under which ISTA will acquire rights to three late-stage ophthalmology compounds.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
AAO 2025 Takeaways: The next frontier in retinal therapeutics arrives
2
AAO 2025 Takeaways: The new era of glaucoma treatment and surgical precision
3
AGC Biologics to manufacture AAVantgarde’s dual-vector gene therapies, AVB-039 and AAVB-081
4
Managing Unique Dry Eye Disease Subtypes in Patients
5














































.png)


